ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1328

Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study

Roslin Jose George1, Noah Frechette1, Iqra Javed1, Bradly Kimbrough2, Sara Achenbach3, Elena Joerns1, Vanessa Kronzer1, John Davis1, Cynthia Crowson1 and Elena Myasoedova1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Rochester, Rochester, MN, 3Mayo Clinic, Rochester, Rochester, MN

Meeting: ACR Convergence 2024

Keywords: Cohort Study, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Carpal tunnel syndrome (CTS) is a common complication of rheumatoid arthritis (RA). However, the occurrence of CTS before RA and the effect of RA serological status on CTS is not well understood. We aimed to assess the occurrence of CTS before and after RA incidence and by serological status compared to individuals without RA. 

Methods: This retrospective population based cohort study included residents of a geographically defined area meeting the 1987 ACR classification criteria for RA between 1980 and 2019. Patients with RA were matched 1:1 with non-RA individuals by age, sex, and RA incidence year. All individuals were followed until death, migration, or 12/31/2023. At least two diagnosis codes no less than 30 days apart were used to identify CTS. Cumulative incidence of CTS adjusting for competing risk of death was assessed. Logistic regression and Cox proportional hazard models were used.

Results: We included 1335 patients with RA (mean age: 56.1 years, 69% females, 63% RF/CCP seropositivity), and 1331 individuals without RA. With a median of 32.5 and 32.9 years of prior medical history in the RA and non-RA individuals, respectively, the overall prevalence of CTS at any time prior to or at RA incidence was 179 (13%) in patients with RA compared to 85 (6%) in non-RA individuals (odds ratio (OR): 2.30; 95% CI: 1.75-3.03). The prevalence of CTS was increased 2 years or more prior to RA incidence/index (OR: 1.55; 95% CI: 1.14-2.10). Among the RA individuals, CTS prior to RA incidence was somewhat more common in RF/CCP negative (76; 15%) than positive (103; 12%) patients, but this association did not reach statistical significance (OR: 1.27; 95% CI: 0.92-1.76). 

During median follow-up of 12.8 and 13.8 years in RA and non-RA, respectively, 154 patients with RA and 102 non-RA developed CTS. After adjusting for age and sex, individuals with RA were 82% more likely to develop CTS when compared to those without RA (age- and sex-adjusted hazard ratio: 1.82; 95% CI: 1.42-2.34) (Figure 1). When further adjusted for age, sex, smoking, and obesity, this association persisted (HR: 1.80, CI: 1.39-2.31).

We found a 37% increase in CTS incidence in patients with seronegative versus seropositive RA, although the difference did not reach statistical significance (age, sex smoking and obesity adjusted hazard ratio: 1.37, CI: 0.99-1.89).

Risk factors for development of CTS after RA incidence included increased BMI (HR: 1.03 per 1 kg/m2, CI: 1.01-1.06) and a lower erythrocyte sedimentation rate (ESR) at RA incidence (HR: 0.99 per 1 mm/hr, CI: 0.98-1.00).

Conclusion: Our study shows that CTS was 1.5-fold more common in individuals with RA (vs non-RA) two years or more prior to RA incidence/ index date, suggesting that it can be an early unrecognized feature of RA disease presentation. The incidence of CTS after RA incidence/ index date is significantly higher in patients with RA versus non-RA controls. Of note, patients with seronegative RA tend to have a higher prevalence of CTS prior to RA and a higher risk of developing CTS after RA onset (vs seropositive RA). These findings suggest the need for increased awareness of the risk of developing RA in patients with persistent CTS and consideration for early rheumatology referral in patients with a high degree of suspicion.  

Supporting image 1


Disclosures: R. George: None; N. Frechette: None; I. Javed: None; B. Kimbrough: None; S. Achenbach: None; E. Joerns: Pfizer, 5; V. Kronzer: None; J. Davis: Girihlet, 10, NLC Health Ventures, 10, Pfizer, 5, Remission Medical, 10; C. Crowson: None; E. Myasoedova: None.

To cite this abstract in AMA style:

George R, Frechette N, Javed I, Kimbrough B, Achenbach S, Joerns E, Kronzer V, Davis J, Crowson C, Myasoedova E. Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/carpal-tunnel-syndrome-is-an-early-unrecognized-feature-of-rheumatoid-arthritis-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/carpal-tunnel-syndrome-is-an-early-unrecognized-feature-of-rheumatoid-arthritis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology